Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.

Department of Molecular Virology, Ohio State University School of Medicine, Ohio State University, Columbus, OH 43210, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 07/2010; 107(27):12210-5. DOI: 10.1073/pnas.1007186107
Source: PubMed

ABSTRACT B-cell chronic lymphocytic leukemia (B-CLL), the most common leukemia in the Western world, occurs in two forms, aggressive (showing for the most part high ZAP-70 expression and unmutated IgH V(H)) and indolent (showing low ZAP-70 expression and mutated IgH V(H)). We found that miR-29a is up-regulated in indolent human B-CLL as compared with aggressive B-CLL and normal CD19(+) B cells. To study the role of miR-29 in B-CLL, we generated Emu-miR-29 transgenic mice overexpressing miR-29 in mouse B cells. Flow cytometric analysis revealed a markedly expanded CD5(+) population in the spleen of these mice starting at 2 mo of age, with 85% (34/40) of miR-29 transgenic mice exhibiting expanded CD5(+) B-cell populations, a characteristic of B-CLL. On average, 50% of B cells in these transgenic mice were CD5 positive. At 2 y of age the mice showed significantly enlarged spleens and an increase in the CD5(+) B-cell population to approximately 100%. Of 20 Emu-miR-29 transgenic mice followed to 24-26 mo of age, 4 (20%) developed frank leukemia and died of the disease. These results suggest that dysregulation of miR-29 can contribute to the pathogenesis of indolent B-CLL.


Available from: Stefan Costinean, Feb 03, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Post-translational modifications of histone proteins represent a fundamental means to define distinctive epigenetic states and regulate gene expression during development and differentiation. Aberrations in various chromatin modulation pathways are commonly used by tumors to initiate and maintain oncogenesis, including lymphomagenesis. Recently, increasing evidence has demonstrated that polycomb group (PcG) proteins, a subset of histone-modifying enzymes known to be crucial for B cell maturation and differentiation, play a central role in malignant transformation of B cells. PcG hyperactivity in B cell lymphomas is caused by over-expression or recurrent mutations of PcG genes, and deregulation of microRNAs or transcription factors such asc-MYC, which regulate PcG expression. Interplays of PcG and microRNA deregulations often establish a vicious signal amplification loop in lymphoma associated with adverse clinical outcomes. Importantly, aberrant enzymatic activities associated with polycomb deregulation, notably those caused by EZH2 gain-of-function mutations, have provided a rationale for developing small-molecule inhibitors as novel therapies. In this review, we summarize our current understandings of PcG-mediated gene silencing, interplays of PcG with other epigenetic regulators such as microRNAs during B cell differentiation and lymphomagenesis, as well as recent advancements in targeted strategies against PcG as a promising therapeutics for B cell malignancies. Copyright © 2015 American Society of Hematology.
    Blood 01/2015; 125(8). DOI:10.1182/blood-2014-10-606822 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: B-cell chronic lymphocytic leukemia (CLL) is the most common human leukemia and dysregulation of the T-cell leukemia/lymphoma 1 (TCL1) oncogene is a contributing event in the pathogenesis of the aggressive form of this disease based on transgenic mouse studies. To determine a role of microRNAs on the pathogenesis of the aggressive form of CLL we studied regulation of TCL1 expression in CLL by microRNAs. We identified miR-3676 as a regulator of TCL1 expression. We demonstrated that miR-3676 targets three consecutive 28-bp repeats within 3'UTR of TCL1 and showed that miR-3676 is a powerful inhibitor of TCL1. We further showed that miR-3676 expression is significantly down-regulated in four groups of CLL carrying the 11q deletions, 13q deletions, 17p deletions, or a normal karyotype compared with normal CD19(+) cord blood and peripheral blood B cells. In addition, the sequencing of 539 CLL samples revealed five germ-line mutations in six samples (1%) in miR-3676. Two of these mutations were loss-of-function mutations. Because miR-3676 is located at 17p13, only 500-kb centromeric of tumor protein p53 (Tp53), and is codeleted with Tp53, we propose that loss of miR-3676 causes high levels of TCL1 expression contributing to CLL progression.
    Proceedings of the National Academy of Sciences 02/2015; 112(7):201500010. DOI:10.1073/pnas.1500010112 · 9.81 Impact Factor
  • Journal of Hematology & Oncology 12/2015; 8(1). DOI:10.1186/s13045-015-0112-x · 4.93 Impact Factor